Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2012-01-10 Director's Dealing
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2012-01-10 English
PRIMARY DOCUMENT
Director's Dealing
2012-01-07 English
PRIMARY DOCUMENT
Director's Dealing
2011-12-07 English
PRIMARY DOCUMENT
Director's Dealing
2011-12-07 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about entering into material definitive agreements related to warrant exchanges, unregistered sales of equity securities, a legal complaint filed against the company, and a press release announcement. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document primarily announces corporate events and agreements, which fits the definition of a Regulatory Filing (RNS) as it does not fit into more specific categories like Capital/Financing Update or Legal Proceedings Report since it covers multiple types of announcements in a current report format. The length is moderate and the document is not merely an announcement of a report but a filing itself with substantive event disclosures.
2011-12-06 English
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, specifically reporting under Item 3.01 regarding a Notice of Delisting or Failure to Satisfy a Continued Listing Rule. The text details the company's notification from Nasdaq about the stock price being below the minimum bid price requirement and the potential consequences including delisting. There is no financial data or report content, only an announcement about the delisting status and compliance timeline. The document length is 3786 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Delisting Announcement (DLST).
2011-11-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.